Amlitelimab is under clinical development by Kymab and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Amlitelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amlitelimab (KY-1005) is under development for the treatment of hidradenitis suppurativa, graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma, alopecia areata, celiac disease, systemic sclerosis and other immune mediated disease. It is administered through intravenous and subcutaneous routes as an infusion. The drug candidate is a humanized bi-specific monoclonal antibody which acts by targeting OX40L. It is developed based on Kymouse technology.
Kymab, a subsidiary of Sanofi, is a biopharmaceutical company that focuses on the development of novel human antibody-based therapies for the treatment of cancer, hematological diseases, and other immune disorders. The company’s pipeline products include KY1005 for the treatment of atopic dermatitis, and KY1044 for the treatment of advanced solid tumors. It is also advancing its pre-clinical candidates including, KY1049 targeting hemophilia A; KY1043 and KY1051 against tumor; and other monoclonal antibody candidates to treat inflammatory diseases, hematological disorders, infectious diseases, and cancer. It employs its proprietary technology platform to discover human antibody candidates against disease targets. Kymab is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Amlitelimab’s drug-specific PTSR and LoA scores, buy the report here.